Reduction in lipoprotein(a) with PCSK9 monoclonal antibody evolocumab (AMG 145): A pooled analysis of more than 1,300 patients in 4 phase II trials

Journal of the American College of Cardiology

Volumn 63, Issue 13, 2014, Pages 1278-1288

  Raal, Frederick J ^a   Giugliano, Robert P ^b   Sabatine, Marc S ^b   Koren, Michael J ^c   Langslet, Gisle ^d   Bays, Harold ^e   Blom, Dirk ^f   Eriksson, Mats ^g   Dent, Ricardo ^h   Wasserman, Scott M ^h   Huang, Fannie ^h   Xue, Allen ^h   Albizem, Moetaz ^h   Scott, Rob ^h   Stein, Evan A ⁱ  

^a UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c Jacksonville Center for Clinical Research   (United States)

^d OSLO UNIVERSITY HOSPITAL   (Norway)

^e LOUISVILLE METABOLIC AND ATHEROSCLEROSIS RESEARCH CENTER   (United States)

^f UNIVERSITY OF CAPE TOWN   (South Africa)

^g KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^h AMGEN INC   (United States)

ⁱ EVLIN Consultants   (United States)

Author keywords

dyslipidemia; evolocumab; lipoprotein(a); PCSK9 inhibition

Indexed keywords

APOLIPOPROTEIN B; EVOLOCUMAB; EZETIMIBE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; PROPROTEIN CONVERTASE SUBTILISIN; SERINE PROTEINASE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; KEXIN; LIPOPROTEIN A; PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9;

ADULT; AGE; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORRELATION ANALYSIS; DRUG EFFICACY; ENZYME INHIBITION; FEMALE; HUMAN; HYPERTENSION; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; OPEN STUDY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SEX; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; DOSE RESPONSE; DRUG EFFECT; DRUG SCREENING; DYSLIPIDEMIA; FAMILIAL HYPERCHOLESTEROLEMIA; HEALTH CARE QUALITY; HIGH RISK POPULATION; LIPID ANALYSIS; LIPOPROTEIN REDUCTION; MAINTENANCE THERAPY; MIDDLE AGED; PHASE 2 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); ULTRACENTRIFUGATION; UNSPECIFIED SIDE EFFECT;

DYSLIPIDEMIA; EVOLOCUMAB; LIPOPROTEIN(A); PCSK9 INHIBITION;

AGED; ANTIBODIES, MONOCLONAL; APOLIPOPROTEINS B; APOPTOSIS; CHOLESTEROL, LDL; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DYSLIPIDEMIAS; FEMALE; HUMANS; LIPOPROTEIN(A); MALE; MIDDLE AGED; PROPROTEIN CONVERTASES; SERINE ENDOPEPTIDASES; TREATMENT OUTCOME; ULTRACENTRIFUGATION;

EID: 84897471477     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2014.01.006     Document Type: Article

References (37)

1. G. Utermann The mysteries of lipoprotein(a) Science 246 1989 904 910
2. R.M. Lawn, N.W. Boonmark, and K. Schwartz et al. The recurring evolution of lipoprotein(a). Insights from cloning of hedgehog apolipoprotein(a) J Biol Chem 270 1995 24004 24009
3. A. Bennet, E. Di Angelantonio, and S. Erqou et al. Lipoprotein(a) levels and risk of future coronary heart disease: large-scale prospective data Arch Intern Med 168 2008 598 608
4. P.R. Kamstrup, A. Tybjaerg-Hansen, R. Steffensen, and B.G. Nordestgaard Genetically elevated lipoprotein(a) and increased risk of myocardial infarction JAMA 301 2009 2331 2339
5. Emerging Risk Factors C S. Erqou, and S. Kaptoge et al. Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality JAMA 302 2009 412 423
6. B.G. Nordestgaard, M.J. Chapman, and K. Ray et al. Lipoprotein(a) as a cardiovascular risk factor: current status Eur Heart J 31 2010 2844 2853
7. R. Clarke, J.F. Peden, and J.C. Hopewell et al. Genetic variants associated with Lp(a) lipoprotein level and coronary disease N Engl J Med 361 2009 2518 2528
8. D.T. Holmes, B.A. Schick, K.H. Humphries, and J. Frohlich Lipoprotein(a) is an independent risk factor for cardiovascular disease in heterozygous familial hypercholesterolemia Clin Chem 51 2005 2067 2073
9. K.M. Kostner, W. Marz, and G.M. Kostner When should we measure lipoprotein (a)? Eur Heart J 34 2013 3268 3276
10. A.M. Scanu, and G.M. Fless Lipoprotein (a). Heterogeneity and biological relevance J Clin Invest 85 1990 1709 1715
11. G.M. Kostner, D. Gavish, B. Leopold, K. Bolzano, M.S. Weintraub, and J.L. Breslow HMG CoA reductase inhibitors lower LDL cholesterol without reducing Lp(a) levels Circulation 80 1989 1313 1319
12. D.J. Rader, W.A. Mann, and W. Cain et al. The low density lipoprotein receptor is not required for normal catabolism of Lp(a) in humans J Clin Invest 95 1995 1403 1408
13. B. Kolski, and S. Tsimikas Emerging therapeutic agents to lower lipoprotein (a) levels Curr Opin Lipidol 23 2012 560 568
14. W.E. Boden, J.L. Probstfield, and T. Anderson et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy N Engl J Med 365 2011 2255 2267
15. F. Raal, R. Scott, and R. Somaratne et al. Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C with PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) randomized trial Circulation 126 2012 2408 2417
16. E.A. Stein, S. Mellis, and G.D. Yancopoulos et al. Effect of a monoclonal antibody to PCSK9 on LDL cholesterol N Engl J Med 366 2012 1108 1118
17. N.R. Desai, P. Kohli, and R.P. Giugliano et al. AMG145, a monoclonal antibody against proprotein convertase subtilisin kexin type 9, significantly reduces lipoprotein(a) in hypercholesterolemic patients receiving statin therapy: an analysis from the LDL-C Assessment With Proprotein Convertase Subtilisin Kexin Type 9 Monoclonal Antibody Inhibition Combined With Statin Therapy (LAPLACE)-Thrombolysis in Myocardial Infarction (TIMI) 57 Trial Circulation 128 2013 962 969
18. R.P. Giugliano, N.R. Desai, and P. Kohli et al. Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 study Lancet 380 2012 2007 2017
19. M.J. Koren, R. Scott, and J.B. Kim et al. Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 as monotherapy in patients with hypercholesterolaemia (MENDEL): a randomised, double-blind, placebo-controlled, phase 2 study Lancet 380 2012 1995 2006
20. D. Sullivan, A.G. Olsson, and R. Scott et al. Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial JAMA 308 2012 2497 2506
21. E.A. Stein, R.P. Giugliano, and M.J. Koren et al. Efficacy and safety of AMG 145, a fully human monoclonal antibody to PCSK9, in hyperlipidaemia patients on various background lipid therapies: pooled analysis of 1359 patients in 4 phase 2 trials Eur Heart J 2014 In press
22. F. Dati, J.R. Tate, and S.M. Marcovina et al. First WHO/IFCC international reference reagent for lipoprotein(a) for immunoassay - Lp(a) SRM 2B Clin Chem Lab Med 42 2004 670 676
23. S. Tsimikas, J.L. Witztum, and E.R. Miller et al. High-dose atorvastatin reduces total plasma levels of oxidized phospholipids and immune complexes present on apolipoprotein B-100 in patients with acute coronary syndromes in the MIRACL trial Circulation 110 2004 1406 1412
24. M.L. Koschinsky, G.P. Cote, B. Gabel, and Y.Y. van der Hoek Identification of the cysteine residue in apolipoprotein(a) that mediates extracellular coupling with apolipoprotein B-100 J Biol Chem 268 1993 19819 19825
25. M.L. Koschinsky, and S.M. Marcovina Structure-function relationships in apolipoprotein(a): insights into lipoprotein(a) assembly and pathogenicity Curr Opin Lipidol 15 2004 167 174
26. H.J. Menzel, H. Dieplinger, and C. Lackner et al. A betalipoproteinemia with an ApoB-100-lipoprotein(a) glycoprotein complex in plasma. Indication for an assembly defect J Biol Chem 265 1990 981 986
27. G. Lippi, and E.J. Favaloro Antisense therapy in the treatment of hypercholesterolemia Eur J Intern Med 22 2011 541 546
28. E.A. Stein, and F.J. Raal Insights Into PCSK9, low-density lipoprotein receptor, and low-density lipoprotein cholesterol metabolism: of mice and man Circulation 127 2013 2372 2374
29. H. Sun, A. Samarghandi, N. Zhang, Z. Yao, M. Xiong, and B.B. Teng Proprotein convertase subtilisin/kexin type 9 interacts with apolipoprotein B and prevents its intracellular degradation, irrespective of the low-density lipoprotein receptor Arterioscler Thromb Vasc Biol 32 2012 1585 1595
30. H. Tavori, D. Fan, and J.L. Blakemore et al. Serum PCSK9 and cell surface low-density lipoprotein receptor: evidence for a reciprocal regulation Circulation 127 2013 2403 2413
31. H.G. Kraft, A. Lingenhel, F.J. Raal, M. Hohenegger, and G. Utermann Lipoprotein(a) in homozygous familial hypercholesterolemia Arterioscler Thromb Vasc Biol 20 2000 522 528
32. HPS2-Thrive Collaborative Group HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment Eur Heart J 34 2013 1279 1291
33. United States Food and Drug Administration. FDA Approves Juxtapid for Homozygous Familial Hypercholesterolemia. Press release. January 29, 2013. Available at: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ ucm333285.htm. Accessed September 10, 2013.
34. United States Food and Drug Administration. FDA approves new orphan drug Kynamro to treat inherited cholesterol disorder. Press release. December 26, 2012. Available at: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ ucm337195.htm. Accessed September 10, 2013.
35. E.J. Schaefer Effects of cholesteryl ester transfer protein inhibitors on human lipoprotein metabolism: why have they failed in lowering coronary heart disease risk? Curr Opin Lipidol 24 2013 259 264
36. Karo Bio. Karo Bio Termintates the Eprotirome Program. Press release. February 14, 2012. Available at: http://www.karobio.com/investormedia/ pressreleaser/pressrelease?pid=639535. Accessed August 8, 2013.
37. P.W. Ladenson, J.D. Kristensen, and E.C. Ridgway et al. Use of the thyroid hormone analogue eprotirome in statin-treated dyslipidemia N Engl J Med 362 2010 906 916